Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Computed Tomography01:10

Computed Tomography

4.2K
Tomography refers to imaging by sections. Computed tomography (CT) is a non-invasive imaging technique that uses computers to analyze several cross-sectional X-rays to reveal minute details about structures in the body.
The technique was invented in the 1970s and is based on the principle that as X-rays pass through the body, they are absorbed or reflected at different levels. In the technique, a patient lies on a motorized platform while a computerized axial tomography (CAT) scanner rotates...
4.2K
Positron Emission Tomography01:29

Positron Emission Tomography

4.0K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.0K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

68
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
68

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Virtual photon-counting micro-CT platform for simulation of head and neck cancer imaging in mice.

Physics in medicine and biology·2026
Same author

Biodegradable nanofibrous drug-eluting seed for sustained intratumoral immunotherapy.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Reconstruction of glymphatic transport fields from subject-specific imaging data, with particular emphasis on cerebrospinal fluid flow and tracer conservation.

ArXiv·2026
Same author

Nano-radiomics of molecular MRI for early amyloid associated patterns in an Alzheimer's disease mouse model via an automatic pipeline.

BMC medical imaging·2026
Same author

Do skeletal muscle bulk and density affect survival outcome in pediatric patients with rhabdomyosarcoma?

La Radiologia medica·2026
Same author

Exercise mitigates high-fat diet-induced cardiac dysfunction via APOE genotype- and immune-dependent mechanisms: A photon-counting CT study in adult mice.

PloS one·2025

Related Experiment Video

Updated: May 28, 2025

Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /T1Magnetic Resonance Imaging
07:26

Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /T1Magnetic Resonance Imaging

Published on: November 20, 2018

6.4K

Nanoparticle Contrast Agents for Photon-Counting Computed Tomography: Recent Developments and Future Opportunities.

Laxman Devkota1,2, Rohan Bhavane1,2, Cristian T Badea3

  • 1Department of Radiology, Baylor College of Medicine, Houston, Texas, USA.

Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology
|February 13, 2025
PubMed
Summary

Photon-counting computed tomography (PCCT) enables advanced spectral imaging. Nanoparticles are promising next-generation contrast agents for PCCT, offering new disease monitoring and treatment prediction opportunities.

Keywords:
cellular imagingcellular trackingcomputed tomographymolecular imagingnanoparticle contrast agentphoton‐counting CTradiomicsspectral CTtheranostics

More Related Videos

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

9.9K
Hybrid µCT-FMT imaging and image analysis
13:45

Hybrid µCT-FMT imaging and image analysis

Published on: June 4, 2015

13.1K

Related Experiment Videos

Last Updated: May 28, 2025

Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /T1Magnetic Resonance Imaging
07:26

Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /T1Magnetic Resonance Imaging

Published on: November 20, 2018

6.4K
Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

9.9K
Hybrid µCT-FMT imaging and image analysis
13:45

Hybrid µCT-FMT imaging and image analysis

Published on: June 4, 2015

13.1K

Area of Science:

  • Medical Imaging
  • Nanotechnology
  • Materials Science

Background:

  • Photon-counting computed tomography (PCCT) represents a significant advancement in CT imaging technology.
  • PCCT offers spectral imaging, superior contrast resolution, and ultrahigh spatial resolution, potentially revolutionizing medical diagnostics.
  • The unique capabilities of PCCT have spurred interest in developing novel contrast agents.

Purpose of the Study:

  • To review recent advancements in nanoparticle contrast agents for spectral PCCT.
  • To explore the potential of these agents in disease interrogation, prediction, and treatment monitoring.
  • To discuss future research and clinical translation opportunities for nanoparticle-based CT contrast agents.

Main Methods:

  • Review of recent scientific literature on nanoparticle contrast agents for PCCT.
  • Analysis of the capabilities of PCCT in conjunction with nanoparticle contrast agents.
  • Discussion of translational considerations for clinical application.

Main Results:

  • Nanoparticles offer a versatile platform for developing next-generation contrast agents for spectral PCCT.
  • These agents hold significant potential for comprehensive disease assessment and treatment outcome monitoring.
  • The advent of PCCT enhances the utility of nanoparticle contrast agents.

Conclusions:

  • Nanoparticle contrast agents are poised to play a crucial role in the era of PCCT.
  • Further research and development are needed to fully realize their clinical potential.
  • Key considerations for clinical translation include efficacy, safety, and manufacturability.